🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
2.380
-0.225 (-8.64%)
Nov 20, 2026, 4:00 PM EST - Market closed

Company Description

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.

The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.

It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections.

The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.

SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.
SCYNEXIS logo
CountryUnited States
Founded1999
IPO DateMay 2, 2014
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees18
CEODavid Angulo

Contact Details

Address:
1 Evertrust Plaza, 13th Floor
Jersey City, New Jersey 07302-6548
United States
Phone201 884 5485
Websitescynexis.com

Stock Details

Ticker SymbolSCYX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001178253
CUSIP Number811292309
ISIN NumberUS8112923094
Employer ID56-2181648
SIC Code2834

Key Executives

NamePosition
Dr. David Gonzalez Angulo M.D.Chief Executive Officer, President and Director
Scott Sukenick J.D.Chief Legal Officer and Corporate Secretary
Sanjay S. Subramanian M.B.A., M.S.Chief Financial Officer
Daniella GiganteVice President of Human Resources and Information Technology
Dr. Todd Minga M.D.Senior Vice President of Research and Development
Dr. Rossana Ferrara-Pontoriero Ph.D.Senior Vice President of Business Development and Portfolio Management

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 5, 2026S-3Registration statement under Securities Act of 1933
Nov 5, 202610-QQuarterly Report
Sep 28, 20268-KCurrent Report
Sep 22, 20268-KCurrent Report
Sep 10, 20268-KCurrent Report
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 12, 2026SCHEDULE 13GFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides